Overcoming immune tolerance in chronic hepatitis B by therapeutic vaccination

Rehermann, 1996, The hepatitis B virus persists for decades after patients’ recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response, Nat Med, 2, 1104, 10.1038/nm1096-1104

Lok, 2017, Hepatitis B cure: from discovery to regulatory approval, J Hepatol, 67, 847, 10.1016/j.jhep.2017.05.008

Zoulim, 2015, Antiviral therapies and prospects for a cure of chronic hepatitis B, Cold Spring Harb Persp Med, 5

Boettler, 2006, Expression of the interleukin-7 receptor alpha chain (CD127) on virus-specific CD8+ T cells identifies functionally and phenotypically defined memory T cells during acute resolving hepatitis B virus infection, J Virol, 80, 3532, 10.1128/JVI.80.7.3532-3540.2006

Protzer, 2012, Living in the liver: hepatic infections, Nat Rev Immunol, 12, 201, 10.1038/nri3169

Knolle, 2014, Hepatic immune regulation and its involvement in viral hepatitis infection, Gastroenterology, 146, 1193, 10.1053/j.gastro.2013.12.036

Thomson, 2010, Antigen-presenting cell function in the tolerogenic liver environment, Nat Rev Immunol, 10, 753, 10.1038/nri2858

Bruner, 2015, Towards an HIV-1 cure: measuring the latent reservoir, Trends Microbiol, 23, 192, 10.1016/j.tim.2015.01.013

Protzer, 2016, “To Be or Not to Be”: immune tolerance in chronic hepatitis B, Gastroenterology, 151, 805, 10.1053/j.gastro.2016.09.038

Wherry, 2015, Molecular and cellular insights into T cell exhaustion, Nat Rev Immunol, 15, 486, 10.1038/nri3862

Utzschneider, 2016, High antigen levels induce an exhausted phenotype in a chronic infection without impairing T cell expansion and survival, J Exp Med, 213, 1819, 10.1084/jem.20150598

Liu, 2014, Enhancing virus-specific immunity in vivo by combining therapeutic vaccination and PD-L1 blockade in chronic hepadnaviral infection, PLoS Pathog, 10, e1003856, 10.1371/journal.ppat.1003856

Kosinska, 2017, Therapeutic vaccination for chronic hepatitis B, Curr Opin Virol, 23, 75, 10.1016/j.coviro.2017.03.011

Kutscher, 2012, Design of therapeutic vaccines: hepatitis B as an example, Microb Biotechnol, 5, 270, 10.1111/j.1751-7915.2011.00303.x

Roggendorf, 2015, The woodchuck, a nonprimate model for immunopathogenesis and therapeutic immunomodulation in chronic hepatitis B virus infection, Cold Spring Harb Persp Med, 5

Kosinska, 2015, Therapeutic vaccination and immunomodulation in the treatment of chronic hepatitis B: preclinical studies in the woodchuck, Med Microbiol Immunol, 204, 103, 10.1007/s00430-014-0379-5

Kosinska, 2010, Therapeutic vaccination in chronic hepatitis B: preclinical studies in the woodchuck, Hepatitis Res Treat, 2010, 817580

Backes, 2016, Protein-prime/modified vaccinia virus Ankara vector-boost vaccination overcomes tolerance in high-antigenemic HBV-transgenic mice, Vaccine, 34, 923, 10.1016/j.vaccine.2015.12.060

Kosinska, 2012, DNA prime-adenovirus boost immunization induces a vigorous and multifunctional T-cell response against hepadnaviral proteins in the mouse and woodchuck model, J Virol, 86, 9297, 10.1128/JVI.00506-12

Kosinska, 2013, Combination of DNA prime—adenovirus boost immunization with entecavir elicits sustained control of chronic hepatitis B in the woodchuck model, PLoS Pathog, 9, e1003391, 10.1371/journal.ppat.1003391

Martin, 2015, TG1050, an immunotherapeutic to treat chronic hepatitis B, induces robust T cells and exerts an antiviral effect in HBV-persistent mice, Gut, 64, 1961, 10.1136/gutjnl-2014-308041

Fontaine, 2015, Anti-HBV DNA vaccination does not prevent relapse after discontinuation of analogues in the treatment of chronic hepatitis B: a randomised trial—ANRS HB02 VAC-ADN, Gut, 64, 139, 10.1136/gutjnl-2013-305707

Lok, 2016, Randomized phase II study of GS-4774 as a therapeutic vaccine in virally suppressed patients with chronic hepatitis B, J Hepatol, 65, 509, 10.1016/j.jhep.2016.05.016

Lobaina, 2017, Chronic hepatitis B: immunological profile and current therapeutic vaccines in clinical trials, Vaccine, 35, 2308, 10.1016/j.vaccine.2017.03.049

Michel, 2015, Therapeutic vaccines in treating chronic hepatitis B: the end of the beginning or the beginning of the end?, Med Microbiol Immunol, 204, 121, 10.1007/s00430-014-0381-y

Xu, 2013, Results of a phase III clinical trial with an HBsAg–HBIG immunogenic complex therapeutic vaccine for chronic hepatitis B patients: experiences and findings, J Hepatol, 59, 450, 10.1016/j.jhep.2013.05.003

Xu, 2008, A randomized controlled phase IIb trial of antigen–antibody immunogenic complex therapeutic vaccine in chronic hepatitis B patients, PLoS One, 3, e2565, 10.1371/journal.pone.0002565

Cavenaugh, 2011, Partially randomized, non-blinded trial of DNA and MVA therapeutic vaccines based on hepatitis B virus surface protein for chronic HBV infection, PLoS One, 6, e14626, 10.1371/journal.pone.0014626

Kondo, 2013, Hepatitis B surface antigen could contribute to the immunopathogenesis of hepatitis B virus infection, ISRN Gastroenterol, 2013, 935295, 10.1155/2013/935295

Tsai, 2018, Mechanisms of hepatitis B virus persistence, Trends Microbiol, 26, 33, 10.1016/j.tim.2017.07.006

Berg, 2017, Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients—FINITE study, J Hepatol, 67, 918, 10.1016/j.jhep.2017.07.012

Honer Zu Siederdissen, 2016, Viral and host responses after stopping long-term nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B, J Infect Dis, 214, 1492, 10.1093/infdis/jiw412

Liaw, 2012, Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update, Hepatol Int, 6, 531, 10.1007/s12072-012-9365-4

Liaw, 2008, Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update, Hepatol Int, 2, 263, 10.1007/s12072-008-9080-3

Hadziyannis, 2012, Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir, Gastroenterology, 143, 10.1053/j.gastro.2012.05.039

Jeng, 2017, Incidence and predictors of HBsAg seroclearance after cessation of nucleos(t)ide analogue therapy in HBeAg negative chronic hepatitis B, Hepatology

Cao, 2017, A potent hepatitis B surface antigen response in subjects with inactive hepatitis B surface antigen carrier treated with pegylated-interferon alpha, Hepatology, 66, 1058, 10.1002/hep.29213

Mason, 2016, HBV DNA integration and clonal hepatocyte expansion in chronic hepatitis b patients considered immune tolerant, Gastroenterology, 151, 10.1053/j.gastro.2016.07.012

European Association for the Study of the Liver, 2017, Electronic address eee, European Association for the Study of the L. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection, J Hepatol, 67, 370, 10.1016/j.jhep.2017.03.021

Gish, 2015, Synthetic RNAi triggers and their use in chronic hepatitis B therapies with curative intent, Antiviral Res, 121, 97, 10.1016/j.antiviral.2015.06.019

Huang, 2017, Preclinical and clinical advances of GalNAc-decorated nucleic acid therapeutics, Mol Therapy Nucl Acids, 6, 116, 10.1016/j.omtn.2016.12.003

Wooddell, 2017, RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg, Sci Transl Med, 9, 10.1126/scitranslmed.aan0241

Vaillant, 2016, Nucleic acid polymers: broad spectrum antiviral activity, antiviral mechanisms and optimization for the treatment of hepatitis B and hepatitis D infection, Antiviral Res, 133, 32, 10.1016/j.antiviral.2016.07.004

Noordeen, 2015, Therapeutic antiviral effect of the nucleic acid polymer REP 2055 against persistent duck hepatitis B virus infection, PLoS One, 10, e0140909, 10.1371/journal.pone.0140909

Al-Mahtab, 2016, Safety and efficacy of nucleic acid polymers in monotherapy and combined with immunotherapy in treatment-naive Bangladeshi patients with HBeAg+ chronic hepatitis B infection, PLoS One, 11, e0156667, 10.1371/journal.pone.0156667

Bazinet, 2017, Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial, Lancet Gastroenterol Hepatol, 2, 877, 10.1016/S2468-1253(17)30288-1

Noordeen, 2013, Nucleic acid polymers prevent the establishment of duck hepatitis B virus infection in vivo, Antimicrob Agents Chemother, 57, 5299, 10.1128/AAC.01005-13

Quinet, 2017, Nucleic acid polymer REP 2139 and nucleos(t)ide analogues act synergistically against chronic hepadnaviral infection in vivo, Hepatology

Guillot, 2017, Inhibition of hepatitis B viral entry by nucleic acid polymers in HepaRG cells and primary human hepatocytes, PLoS One, 12, e0179697, 10.1371/journal.pone.0179697

Real, 2017, Nucleic acid-based polymers effective against hepatitis B Virus infection in patients don’t harbor immunostimulatory properties in primary isolated liver cells, Sci Rep, 7, 43838, 10.1038/srep43838

Feeney, 2014, Antiviral treatment of hepatitis C, BMJ, 348, g3308, 10.1136/bmj.g3308

Cohen, 2013, Antiretroviral treatment of HIV-1 prevents transmission of HIV-1: where do we go from here?, Lancet, 382, 1515, 10.1016/S0140-6736(13)61998-4

Bogomolov, 2016, Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: first results of a phase Ib/IIa study, J Hepatol, 65, 490, 10.1016/j.jhep.2016.04.016

Klumpp, 2018, Efficacy of NVR 3-778, alone and in combination with pegylated interferon, vs entecavir in uPA/SCID mice with humanized livers and HBV infection, Gastroenterology, 154, 10.1053/j.gastro.2017.10.017

Berke, 2017, Capsid assembly modulators have a dual mechanism of action in primary human hepatocytes infected with hepatitis B virus, Antimicrob Agents Chemother, 61, 10.1128/AAC.00560-17

Schinazi, 2018, Towards HBV curative therapies, Liver Int Off J Int Assoc Study Liver, 38, 102

Mak, 2017, Hepatitis B core protein as a therapeutic target, Expert Opin Therapeutic Targets, 21, 1153, 10.1080/14728222.2017.1397134

Ko, 2017, Novel viral and host targets to cure hepatitis B, Curr Opin Virol, 24, 38, 10.1016/j.coviro.2017.03.019